Jump Financial LLC Makes New $1.06 Million Investment in Bausch Health Cos Inc. $BHC

Key Points

• Jump Financial LLC has invested approximately $1.06 million in Bausch Health Companies Inc., acquiring 163,078 shares during the first quarter of the year.
• Despite a strong revenue performance of $2.57 billion, Bausch Health reported an EPS of $0.90, missing estimates and showing a net margin of only 0.99%.
• Insider trading activity has increased with Director John Paulson purchasing over 34 million shares, boosting his stake significantly, which indicates strong insider confidence in the company's future.

Jump Financial LLC acquired a new position in Bausch Health Cos Inc. (NYSE:BHC - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 163,078 shares of the company's stock, valued at approximately $1,055,000.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. Toronto Dominion Bank boosted its position in Bausch Health Cos by 1.0% in the fourth quarter. Toronto Dominion Bank now owns 167,212 shares of the company's stock worth $1,350,000 after purchasing an additional 1,712 shares during the last quarter. Wells Fargo & Company MN boosted its position in Bausch Health Cos by 7.9% in the fourth quarter. Wells Fargo & Company MN now owns 25,907 shares of the company's stock worth $209,000 after purchasing an additional 1,896 shares during the last quarter. SBI Securities Co. Ltd. boosted its position in Bausch Health Cos by 244.2% in the first quarter. SBI Securities Co. Ltd. now owns 4,230 shares of the company's stock worth $27,000 after purchasing an additional 3,001 shares during the last quarter. Cary Street Partners Financial LLC purchased a new position in shares of Bausch Health Cos during the 1st quarter valued at $27,000. Finally, Caitong International Asset Management Co. Ltd purchased a new position in shares of Bausch Health Cos during the 1st quarter valued at $27,000. Hedge funds and other institutional investors own 78.65% of the company's stock.

Bausch Health Cos Stock Performance

Shares of NYSE:BHC traded down $0.32 during midday trading on Wednesday, reaching $7.37. 888,677 shares of the company traded hands, compared to its average volume of 2,681,347. The company has a quick ratio of 0.98, a current ratio of 1.31 and a debt-to-equity ratio of 141.90. Bausch Health Cos Inc. has a 12 month low of $4.25 and a 12 month high of $9.85. The firm has a market capitalization of $2.73 billion, a price-to-earnings ratio of 28.37 and a beta of 0.48. The firm's fifty day moving average price is $6.78 and its two-hundred day moving average price is $6.08.

Bausch Health Cos (NYSE:BHC - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The company reported $0.90 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.97 by ($0.07). Bausch Health Cos had a net margin of 0.99% and a negative return on equity of 852.36%. The company had revenue of $2.57 billion for the quarter, compared to the consensus estimate of $2.47 billion. Bausch Health Cos has set its FY 2025 guidance at EPS. On average, equities analysts expect that Bausch Health Cos Inc. will post 4.41 earnings per share for the current year.

Insider Activity

In related news, Director John Paulson acquired 34,721,118 shares of the firm's stock in a transaction that occurred on Thursday, August 14th. The shares were bought at an average cost of $9.00 per share, for a total transaction of $312,490,062.00. Following the purchase, the director owned 70,755,869 shares in the company, valued at $636,802,821. This trade represents a 96.35% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In the last 90 days, insiders acquired 44,316,834 shares of company stock worth $369,628,560. Insiders own 19.97% of the company's stock.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen raised Bausch Health Cos from a "hold" rating to a "buy" rating in a research report on Saturday, August 2nd. Three research analysts have rated the stock with a Hold rating, According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $9.00.

Bausch Health Cos Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.